EDIT - Company ID 0001650664
The table below shows Editas Medicine, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $40.52M | $32.31M | $78.12M | $19.71M | $25.54M | $90.73M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $89.95M | $199.25M | $177.65M | $174.96M | $142.51M | $158.00M |
| SG&A |
Editas Medicine, Inc. reported annual revenue of $40.52M for fiscal year 2025. That is up 25.4% from $32.31M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $6.05M (FY 2016) to $40.52M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $49.90M |
| $71.99M |
| $69.65M |
| $70.70M |
| $76.18M |
| $67.58M |
| Operating income | -$160.01M | -$251.15M | -$169.18M | -$225.95M | -$193.15M | -$134.84M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | - |
| Net income | -$160.06M | -$237.09M | -$153.22M | -$220.43M | -$192.50M | -$115.98M |
| EPS (diluted) | -$1.80 | -$2.88 | -$2.02 | -$3.21 | -$2.85 | -$1.98 |